The next era of gene editing will be an agnostic disease
To wire Health Summit Last week, Harvard Biochemist and Gene Pioneer David Liu said his laboratory plans for reporting on a single strategy this year that could treat many unrelated diseases. It is called it about an agnostic therapeutic genome.
“Sounds kind of crazy, but there is actually a very good molecular biological reason why it could be possible,” the audience said in Boston, stopping with short details.
Current treats for editing genes are currently being developed for several rare and hereditary genetic diseases. One treatment for editing a gene, called Cagevy, is approved and available commercial to treat cell diseases and a related blood disorder called Beta Thalashemia. Earlier this year, KJ Muldoon, a children’s boy born with a frequently fatal genetic disease that causes the ammonia to build in his blood, was saved with a custom gene treatment – first.
These treatments work targeting specific mutations related to these diseases. But they can develop expensive and must be designed for the patient’s specific population. Sometimes these populations of the patient can be very small, as in the case of a baby KJ. Its condition is called a lack of CPS1, affects only one in 1.3 million live births.
Liu predicts the future in which an gene approach can be used in the gene editing in several different diseases, regardless of which organ or tissues affect or their genetic cause. He says that this type of simplified strategy is needed because they are collective, there are so few diseases, and would impractically design treatments for each. Global genes, organization advocacy Rare diseases, estimates that there are at least 10,000 rare diseases that affect more than 400 million people around the world.
Photo: Vail Fucci
“Genetic disease as a whole is not so rare. It actually is prevailing from cancer or HIV / AIDS many times,” Liu said. “We urgently need these ways to act directly with the root cause of these genetic diseases.”